Androniki Bili

855 total citations
17 papers, 619 citations indexed

About

Androniki Bili is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Androniki Bili has authored 17 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 4 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Androniki Bili's work include Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Androniki Bili is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Androniki Bili collaborates with scholars based in United States, Austria and Australia. Androniki Bili's co-authors include Mary Chester Wasko, H. Lester Kirchner, Jana L. Antohe, Stephanie J. Morris, Jennifer Sartorius, Xiaoqin Tang, Xiaowei Yan, Tarun Sharma, John J. Condemi and Eric D. Newman and has published in prestigious journals such as Circulation, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Androniki Bili

17 papers receiving 600 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Androniki Bili United States 12 410 99 86 82 70 17 619
Eva Salgado Spain 12 506 1.2× 260 2.6× 31 0.4× 55 0.7× 84 1.2× 22 804
Camelia Doina Vrabie Romania 9 281 0.7× 122 1.2× 27 0.3× 76 0.9× 50 0.7× 27 517
Cibo Huang China 15 366 0.9× 162 1.6× 42 0.5× 162 2.0× 74 1.1× 45 657
G S Alarcón United States 12 394 1.0× 93 0.9× 21 0.2× 37 0.5× 70 1.0× 23 585
Shinobu Waga Japan 14 118 0.3× 87 0.9× 60 0.7× 67 0.8× 30 0.4× 58 560
Maaike Heslinga Netherlands 8 385 0.9× 159 1.6× 70 0.8× 64 0.8× 49 0.7× 19 534
Álvaro Danza Uruguay 10 553 1.3× 282 2.8× 22 0.3× 51 0.6× 67 1.0× 35 763
Naomi B. Klarenbeek Netherlands 16 716 1.7× 161 1.6× 63 0.7× 65 0.8× 55 0.8× 36 885
Marco Ulises Martínez‐Martínez Mexico 14 334 0.8× 84 0.8× 23 0.3× 90 1.1× 87 1.2× 47 594
Chagai Grossman Israel 17 150 0.4× 191 1.9× 161 1.9× 285 3.5× 66 0.9× 41 788

Countries citing papers authored by Androniki Bili

Since Specialization
Citations

This map shows the geographic impact of Androniki Bili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Androniki Bili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Androniki Bili more than expected).

Fields of papers citing papers by Androniki Bili

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Androniki Bili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Androniki Bili. The network helps show where Androniki Bili may publish in the future.

Co-authorship network of co-authors of Androniki Bili

This figure shows the co-authorship network connecting the top 25 collaborators of Androniki Bili. A scholar is included among the top collaborators of Androniki Bili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Androniki Bili. Androniki Bili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Metz, Martin, Sonja Ständer, Leigh Nattkemper, et al.. (2025). Safety and efficacy of barzolvolimab, an anti–KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study. Journal of the American Academy of Dermatology. 93(6). 1596–1599. 1 indexed citations
2.
3.
Russell, Kevin L., Richard Rupp, Javier O Morales-Ramirez, et al.. (2022). A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults. Human Vaccines & Immunotherapeutics. 18(5). 2046960–2046960. 20 indexed citations
4.
Aletaha, Daniel, Clifton O. Bingham, George Karpouzas, et al.. (2021). Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open. 7(1). e001465–e001465. 14 indexed citations
5.
Sharma, Tarun, et al.. (2016). Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. Journal of the American Heart Association. 5(1). 111 indexed citations
6.
Berger, Andrea, et al.. (2014). Low vitamin D level is not associated with increased incidence of rheumatoid arthritis. Rheumatology International. 34(10). 1475–1479. 9 indexed citations
7.
Schroeder, Lisa L., Xiaoqin Tang, Mary Chester Wasko, & Androniki Bili. (2014). Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. Rheumatology International. 35(6). 1059–1067. 12 indexed citations
8.
Bili, Androniki, et al.. (2013). Aspirin Use in Rheumatoid Arthritis Patients with Increased Risk of Cardiovascular Disease. PubMed. 2013. 1–4. 3 indexed citations
9.
Bili, Androniki, Xiaoqin Tang, Shruthi Pranesh, et al.. (2013). Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis. Arthritis Care & Research. 66(3). 355–363. 62 indexed citations
10.
Bili, Androniki, et al.. (2012). Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis. The Journal of Rheumatology. 39(5). 946–948. 4 indexed citations
11.
Antohe, Jana L., Androniki Bili, Jennifer Sartorius, et al.. (2011). Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy. Arthritis Care & Research. 64(2). 215–221. 70 indexed citations
12.
Bili, Androniki, Jennifer Sartorius, H. Lester Kirchner, et al.. (2011). Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients. JCR Journal of Clinical Rheumatology. 17(3). 115–120. 65 indexed citations
13.
Morris, Stephanie J., Mary Chester Wasko, Jana L. Antohe, et al.. (2010). Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care & Research. 63(4). 530–534. 106 indexed citations
14.
Bili, Androniki, et al.. (2010). Patterns of preventive health services in rheumatoid arthritis patients compared to a primary care patient population. Rheumatology International. 31(9). 1159–1165. 13 indexed citations
15.
16.
Bili, Androniki, Arthur J. Moss, Charles W. Francis, et al.. (2000). Anticardiolipin Antibodies and Recurrent Coronary Events. Circulation. 102(11). 1258–1263. 56 indexed citations
17.
Bili, Androniki, et al.. (1999). Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. Journal of Allergy and Clinical Immunology. 104(5). 1060–1065. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Salgado Breakdown of academic impact, for papers by Camelia Doina Vrabie Breakdown of academic impact, for papers by Cibo Huang Breakdown of academic impact, for papers by G S Alarcón Breakdown of academic impact, for papers by Shinobu Waga Breakdown of academic impact, for papers by Maaike Heslinga Breakdown of academic impact, for papers by Álvaro Danza Breakdown of academic impact, for papers by Naomi B. Klarenbeek Breakdown of academic impact, for papers by Marco Ulises Martínez‐Martínez Breakdown of academic impact, for papers by Chagai Grossman
Rankless by CCL
2026